Phase II interventional trial for the assessment of histological responses in all resected colorectal cancer liver metastases after preoperative cetuximab-based chemotherapy. [Ensayo clinico fase II para la evaluacion de las respuestas histologicas de todas las metastasis hepaticas resecadas en pacientes con Cancer colorectal metastasico tras quimioterapia preoperatoria basada en Cetuximab]

Trial Profile

Phase II interventional trial for the assessment of histological responses in all resected colorectal cancer liver metastases after preoperative cetuximab-based chemotherapy. [Ensayo clinico fase II para la evaluacion de las respuestas histologicas de todas las metastasis hepaticas resecadas en pacientes con Cancer colorectal metastasico tras quimioterapia preoperatoria basada en Cetuximab]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Liver metastases
  • Focus Therapeutic Use
  • Acronyms ERBIMET
  • Most Recent Events

    • 07 Dec 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 10 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top